We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Novel Method Identifies Fat Malabsorption

By LabMedica International staff writers
Posted on 10 Sep 2014
Print article
Agilent Technologies\' Series 1200 high pressure liquid chromatography (HPLC) system
The Series 1200 high pressure liquid chromatography (HPLC) system (Photo courtesy of AGILENT)
A novel clinical test known as the Serum Retinyl Palmitate Test (RP) has been assessed and validated for the diagnosis of fat malabsorption, and compared to the fecal fat test (FFT).

The differential diagnosis for malabsorptive diarrhea is broad, encompassing luminal, mucosal and lymphatic disorders involving different organ systems and the possibility of undiagnosed systemic endocrine or immunodeficient diseases also highlights the importance of a thorough work-up.

Clinical biochemists at the University of Calgary (AB, Canada) carried out a case-control study on patients identified with chronic diarrhea, defined as persistent symptoms for greater than four weeks, and suspected malabsorption. Healthy control subjects were also recruited. Blood samples were collected at intervals after the administration of oil-soluble vitamin A. A fecal fat test was conducted on samples of patients after the consumption of 100 grams of a fat diet. Patients were defined as malabsorbers if the 72-hour stool fat excretion was greater than 5.9 g/day.

Serum levels of retinol (vitamin A) and RP were measured by reversed-phase high pressure liquid chromatography (HPLC; Waters; Milford, MA, USA). The detection limit for retinol was 0.18 mg/L and for retinyl-palmitate, it was 0.02 mg/L. Sixteen patients completed this study, 8 cases and 8 control subjects. Fecal fat results were available for 15/16 patients. The sensitivity of the FFT was 100%, but the FFT specificity was 42%, as 4/7 control patients were identified as malabsorbers. Cases with short bowel syndrome (SBS) had the lowest RP levels, but this did not meet statistical significance. There was no significant difference for serum RP levels when comparing cases and control patients.

The authors concluded that the RP test did identify patients with severe malabsorption secondary to SBS, but the performance of the RP test in patients with malabsorption from non-SBS etiologies was poor. However, the so-called gold standard, 72-hour FFT, had poor performance characteristics, highlighting the need for more useful diagnostics in identifying malabsorption. The study was published on August 8, 2014, in the journal Clinica Chimica Acta.

Related Links:

University of Calgary 
Waters 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.